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background: Hypertrophic cardiomyopathy (HCM) is a sudden death predisposing disease often caused by sarcomeric gene mutations. Several 
metabolic storage diseases can also mimic the phenotypic expression of HCM. We sought to determine the spectrum and prevalence of sarcomeric 
and metabolic gene mutations in patients with clinically suspected HCM.
Methods: DNA sequence analysis of 9 sarcomeric myofilament genes (MYH7, MYBPC3, TNNT2, TNNI3, TNNC1, TPM1, MYL2, MYL3, ACTC) and 3 HCM 
phenocopy genes (GLA, PRKAG2, and LAMP2) was performed for 2,382 unrelated patients referred to Transgenomic for FAMILION® HCM genetic 
testing. Variants were evaluated with respect to mutation type, location, predicted effect upon the gene products, prior literature, and more than 400 
control individuals representative of major U.S. populations.
results: 40% (957/2382) of cases tested positive for 534 unique pathogenic or putatively pathogenic sarcomeric gene mutations. MYBPC3 (24%) 
and MYH7 (14%) accounted for the majority of mutations identified. Twelve percent of sarcomeric mutation-positives cases harbored more than one 
mutation in one or genes. In addition, 3% (69/2382) of cases tested positive for 45 unique mutations in GLA, LAMP2, or PRKAG2. Approximately 1% 
of cases harbored both sarcomeric and metabolic gene mutations.
conclusion: Among patients referred by cardiologists throughout North America for HCM clinical genetic testing, the yield of sarcomeric HCM 
was 40%, consistent with the yield expected for a cohort comprised of patients with moderate-to-high clinical suspicion for HCM. Importantly, 
this analysis suggests 1 in 30 suspected HCM patients may suffer metabolic storage diseases mimicking HCM. An accurate diagnosis is relevant 
because important differences exist between sarcomeric HCM and HCM phenocopies in clinical course, management, and prognosis. Additionally, 
the co-occurrence of sarcomeric and metabolic gene mutations suggests that disease progression in sarcomeric HCM may be influenced by other, 
potentially unrecognized, genetic conditions.
